# EDGAR Filing Document

**Accession Number:** 0000882291
**File Stem:** 0001683168-25-006360
**Filing Date:** 2025-8
**Character Count:** 20140
**Document Hash:** c813b83ad6391fef00351c6c5b465799
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-006360.hdr.sgml**: 20250821

**ACCESSION NUMBER**: 0001683168-25-006360

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 34

**CONFORMED PERIOD OF REPORT**: 20250821

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250821

**DATE AS OF CHANGE**: 20250821

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AETHLON MEDICAL INC
- **CENTRAL INDEX KEY:** 0000882291
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133632859
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37487
- **FILM NUMBER:** 251240316

**BUSINESS ADDRESS:**
- **STREET 1:** 11555 SORRENTO VALLEY ROAD, SUITE 203
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 619-941-0360

**MAIL ADDRESS:**
- **STREET 1:** 11555 SORRENTO VALLEY ROAD, SUITE 203
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BISHOP EQUITIES INC
- **DATE OF NAME CHANGE:** 19930602

?xml version='1.0' encoding='ASCII'? AETHLON MEDICAL, INC. 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 21, 2025**

**Aethlon Medical, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-37487** | **13-3632859** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **11555 Sorrento Valley Road, Suite 203**<br> **San Diego, California** | **92121** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(619) 941-0360**

**N/A** 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| **Common Stock, $0.001 par value per share**<br> **AEMD** | **The Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosures.**

On August 20, 2025, Aethlon Medical, Inc. (the "Company") made available an updated corporate presentation (the "Presentation") that may be used by the Company in connection with presentations at conferences and investor meetings. The Presentation can be found on the Company's website, www.aethlonmedical.com. The Presentation is furnished as Exhibit 99.1 hereto.

The information in the Presentation is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Presentation will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of the information in this Current Report on Form 8-K with respect to the Presentation is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Presentation is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

**Item 9.01 Financial Statements and Exhibits.** 

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | [Presentation Materials](aemd_ex9901.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL Document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: August 21, 2025 | **Aethlon Medical, Inc.** | **Aethlon Medical, Inc.** |
|  | By: | /s/ James B. Frakes |
|  | Name:<br> Title: | James B. Frakes<br> *Chief Executive Officer and Chief Financial Officer* |

---

## Exhibit 99.1

**Exhibit 99.1**

![](image_040.jpg)

Corporate Presentation The Hemopurifier®

![](image_041.jpg)

![](image_042.jpg)

Investment Highlights 3 • Patented Aethlon Hemopurifier® blood purification device • Early clinical trials have shown enveloped virus and extracellular vesicle (EV\*) clearance both in vitro and in patients • Two FDA "Breakthrough Device" designations • Advanced/metastatic cancer • Life - threatening viral infections without approved therapies • Oncology trial enrolling patients in Australia near term opportunity for clinical data readouts • Designed to target multiple therapeutic pathways within oncology and infectious disease • Active R&D in Long COVID • Broad patent portfolio supporting long - term competitive advantage • Multiple future expansion opportunities across high - value therapeutic areas • Capital - efficient clinical development supported by Australia's 43.5% R&D rebate program \* EV = extracellular vesicles, which include exosomes

![](image_043.jpg)

The Aethlon Hemopurifier® » Administered in 167 Hemopurifier sessions in 41 patients with a favorable safety profile 1 » Proprietary, patented technology » Demonstrated clearance of life - threatening enveloped viruses » Designed to clear tumor - derived EVs, and their associated cargo (Oncology) 1 Aethlon clinical safety database 4

![](image_044.jpg)

Unique Mechanism of Action How It Works: • Plasma separation: Obviates the need for plasmapheresis or plasma exchange • Size exclusion: Keeps larger, unwanted particles within the lumen of the device while allowing smaller targets to contact the proprietary affinity resin of the Hemopurifier • Targeted Binding: A plant lectin (GNA) captures extracellular vesicles and enveloped viruses by attaching to sugars on their surface 5

![](image_045.jpg)

Hemopurifier Platform – Multi - Disease Potential Platform Enablers: Manufacturing, regulatory, IP foundation Enrolling in Australia: FDA Breakthrough Device Oncology 6 Life Threatening Viral Infections Exploratory Indications (Platform Potential) Preclinical/clinical - readiness; FDA Breakthrough Device Concept validation and preclinical scoping Reg/Launch PMA Trial Clinical (safety) Preclinica l Concept

![](image_046.jpg)

Oncology 7

![](image_047.jpg)

Why the Hemopurifier Targets Tumor - Derived EVs Extracellular Vesicles (EVs) including small EVs known as exosomes (50 - 150nm) are lipid bilayer enclosed nanoparticles released by all cell types including tumor cells » EVs are involved in cell - to - cell communication » Extracellular Vesicles contain cargo including nucleic acids, proteins, lipids and microRNAs » Tumor - Derived EVs have more mannose on their surface than non - Tumor - Derived (Anal Biochem. 2019 Sep 1;580:21 - 29.) Specifically, EVs: • Linked to the spread of cancer (metastases) • Play a role in immune system evasion by the tumor • Facilitate chemotherapy resistance • EVs bearing PD - L1 interfere with antibody - based treatments (e.g., PD - 1 antibody therapies such as Keytruda and Opdivo) Zhang L and Yu D. Biochim Acta Rev Cancer 2019;1872 (2): 455 - 468. 8

![](image_048.jpg)

Immunotherapy Market & Unmet Need Market Size • PD - 1/PD - L1 Inhibitors: ~$62B in 2025 → ~$120B by 2030 • Checkpoint Inhibitors (PD - 1, PD - L1, CTLA - 4): ~$26B in 2024 → ~$107B by 2034 • PD - 1 Inhibitor Drugs: ~$48.7B in 2025 → ~$179.8B by 2034 Response Challenge Only 30 - 40% have a lasting clinical response to anti - PD - 1 monotherapy • ~40% non - response with anti - PD - 1 + anti - CTLA - 4 combos Hemopurifier Opportunity • Targets the 60 – 70% of patients who do not respond • Novel mechanism: Removes tumor - derived exosomes that leads to T cell exhaustion • Potential to enhance immunotherapy responsiveness • Even partial penetration → Possible Multi - billion - doll ar i mpact Sources: Mordor Intelligence, Persistence Market Research, Precedence Research, ScienceDirect, NIH/PMC 0% 10% 20% 30% 40% 50% 60% 70% Responders (~30 - 40%) Non - Responders (~60 - 70%) Patient Share (%) 65% 35% Hemopurifier Opportunity 9

![](image_049.jpg)

In Vitro Removal Of Cancer - Derived EVs Demonstrated 10 In Vitro Experiments (Miniature Hemopurifier): • Multiple Tumor Types – Removed 92 - 99 % of buffer suspended EVs (Marleau AM , Jacobs MT, Gruber N, e t al . Cance r Res 2020 ; 80 (16 _Supplement) : 4509 .) • Patient Plasma – Removed EVs directly from plasma sample of a non - small cell lung cancer patient (NSCLC) (Brown MP, Matos M, Clarke S, Coates PT, et al . medRxiv . Preprint posted on March 21 , 2025 . doi : https : //doi . org/ 10 . 1101 / 2025 . 03 . 20 . 25323761 .) In Vivo Experiments : • Severe COVID - 19 Patient – Reduced total exosome concentrations over 8 HP treatments (Amundson DE, Shah US, de Necochea - Campion R, et al Front Med (Lausanne) . 2021 Oct 8 ; 8 : 744141 .) • Head & Neck Cancer Patient – Reduced total EV concentrations after 2 HP treatments 21 days apart (Brown MP, Matos M, Clarke S, Coates PT, et al. medRxiv. Preprint posted on March 21, 2025. doi: https://doi.org/10.1101/2025.03.20.25323761.)

![](image_050.jpg)

In Vivo Reduction of Exosomes in Head & Neck Cancer Single subject with head and neck cancer following 2 distinct Hemopurifier treatments » The total nanoparticle counts decreased following each of the treatments. » Slowly rose 7 days following the treatment to levels that were below the baseline measurement Brown MP, Matos M, Clarke S, Coates PT, et al. medRxiv. Preprint posted on March 21, 2025. doi: https://doi.org/10.1101/2025.03.20.25323761.)

![](image_051.jpg)

12 Progress in Australian Hemopurifier® Oncology Trial Trial Status • 3 sites open as of February 2025 • 3 participants received a single HP treatment in Cohort 1 • Protocol amendment broadens participant eligibility to allow all treatment regimens that include an anti PD - 1 agent • Cohort 2 now open for enrollment - 2 HP treatments during a 1 - week period • Cohort 3 would follow (3 - HP treatments during a 1 - week period) Trial Design: Safety, feasibility, and dose - finding study in patients with stable or progressive malignancies while on pembrolizumab or nivolumab. ANZCTR Link Safety Outcomes • No dose - limiting toxicities or device - related serious adverse events at 7 - day follow - up • Data Safety Monitoring Board evaluated data from initial cohort and recommended advancement to next clinical cohort Next Steps • Review and interpret lab findings • Present data to regulatory agencies in a pre - PMA meeting • Engage potential partners Upcoming Data • Central lab results on EV removal after Hemopurifier® treatment from first cohort • Central lab results on anti - tumor CD8 T cell changes after Hemopurifier® treatment from first cohort

![](image_052.jpg)

Virology 13

![](image_053.jpg)

Hemopurifier® for Emerging Viral Threats Source: World Health Organization: Prioritizing diseases for research and development in emergency contexts 14 We believe the Aethlon Hemopurifier® is Uniquely Positioned as an Early Treatment Option for Future Bioattacks or Pandemic Threats » The next bioattack or pandemic is likely to occur with an enveloped virus » Enveloped viruses contain mannose structures that are the target for the affinity resin in the Aethlon Hemopurifier® » During a bioattack or pandemic there will likely be delays in the time to develop effective anti - viral therapies and/or vaccines » Removal of viruses from the bloodstream in critically ill patients may provide benefit during the time it takes to generate effective therapies (i.e. could provide a layered defense) » Extensive in vitro and in vivo data with our Hemopurifier has demonstrated removal of enveloped virus (e.g., Ebola, H5N1, H1N1, SARS - CoV - 2, etc.) and disease contributing extracellular vesicles We believe the Hemopurifier's demonstrated removal of enveloped viruses and extracellular vesicles from a patient's blood presents a unique, broad spectrum, treatment option

![](image_054.jpg)

In Vitro and In Vivo Removal of Enveloped Viruses • Hepatitis C • Ebola • Marburg • Dengue • Chikungunya • HIV • Ebola • SARs - CoV - 2 15 • West Nile Virus • H5N1 (Bird Flu) • 1918 Spanish Flu • EBV • MERS - CoV • SARs - CoV - 2 Spike Protein • SARs - CoV2 (7 variants) In vitro: • HIV In vivo (Human Subjects): • Hepatitis C

![](image_055.jpg)

Pre - Clinical Research - Long COVID Background: • Long COVID is the persistence of symptoms at least 3 months following acute infection with the SARS - CoV - 2 virus • Global incidence of Long COVID is estimated to be 400,000,000 with an economic burden of 1 trillion dollars/year (Nat Med 30, 2148 – 2164 (2024). • Extracellular vesicles including those containing the Spike protein have been implicated in the pathogenesis of Long COVID (Fanelli et al. Extracell Vesicles Circ Nucleic Acids 2024;5:417 - 370) Findings: • Large EVs (microvesicles) in Long COVID patient samples showed significantly greater binding to GNA than those in COVID – recovered patients. • Smaller EVs in Long COVID patient samples bound to the Hemopurifier® GNA affinity resin Next steps: EV Cargo Analysis for Mediators of Long COVID Pathogenesis: • Viral persistence: SARs – CoV - 2 RNA & spike protein • HHV reactivation: EBV in EVs • Immune and coagulation dysregulation: microRNAs and cytokines • T cell Exhaustion: PD - L1 in EV 1 P 6 r es e nte d at Keystone Long COVID Symposium 12AUG 2025

![](image_056.jpg)

Pre - Clinical - Platelet - Derived Microparticles (MPs) Background: • Microparticles derived from activated platelets (PD - EVs) are elevated in a myriad of diseases and associated with disease activity: • SLE (Lupus) • Rheumatoid Arthritis • Cancer • Systemic Sclerosis • Multiple Sclerosis • Alzheimer's Disease • Sepsis • Acute and Long COVID Methods: • Normal Human Plasma was run over the Hemopurifier • Serial samples were collected for EV measurement Findings: • 98.5% removal of platelet - derived microparticles at a timepoint equivalent to a 4 - hour HP treatment. Implications: • The results of this study support the current Australian Clinical Trial in Oncology as well as open the investigation of the Hemopurifier in many indications . de Necochea Campion, R, Pesqueira M, LaRosa SP. bioRxiv. Preprint posted May 11, 2025. doi: https://doi.org/10.1101/2025.05.09.652772 17

![](image_057.jpg)

Pre - Clinical - Organ Transplantation Background: • Machine Perfusion (MP) following kidney recovery improves outcomes compared to static cold storage • MP is associated with the release of EVs and microRNAs, which are linked to delayed graft function and acute rejection Hypothesis: The Hemopurifier would remove EVs and associated miRNAs from renal perfusates that had undergone MP Methods: • Perfusates following machine perfusion of recovered kidneys were run over the Hemopurifier • Serial samples taken for EV and miRNA analysis Findings: • Both small EVs and Large EVs removed from renal perfusates • NanoString analysis of miRNA identified 5 species potentially involved in renal dysfunction, significantly depleted following Hemopurifier treatment (p ≤ 0 . 05) . Implications: • The Hemopurifier® could be "bolted on" to existing MP platforms to further improve outcomes renal transplantation de Necochea Campion R, Pesqueira M, Vallejos P, et al. Transpl Immunol. 2025 May;90:102215. 18

![](image_058.jpg)

United States International Patent Protection Extending to 2044 (Including Pending Applications) Issued Patents: • 3 patents issued covering extracorporeal removal of microvesicular particles, patent protection until 2029 • 1 patent to be issued (issue fee paid) covering treatment of coronavirus infections and symptoms thereof, patent protection until 2041 once issued Patent Applications: • 2 applications pending covering removal of Covid - 19 viral particles and associated exosomes, patent protection until 2042 if granted • 1 application pending covering removal of exosomes, ectosomes, miRNAs, circulating nucleic acids, and viral particles with transplantation, patent protection until 2044 if granted Issued Patents: • 14 patents covering exosomes and microvesicular particle removal • Patent protection extending to 2031 in Germany, France, Great Britain, and Spain • Patent protection extending to 2027 in Canada, Switzerland, Italy, Netherlands, Sweden, Hong Kong, Demark and Ireland • 4 patents covering removal of Covid - 19 viral particles and associated exosomes. • Patent protection extending to 2041 in Unitary Patent member states, Switzerland, Great Britain and Spain Patent Applications: • 13 pending applications directed to extracorporeal removal of microvesicular particles, removal of Covid - 19 viral particles and associated exosomes, removal of exosomes, ectosomes, miRNAs, circulating nucleic acids, and viral particles with transplantation patent protection to 2044 if granted • 1 pending application directed to removal of exosomes, ectosomes, miRNAs, circulating nucleic acids, and viral particles associated with tissues selected for transplantation, patent protection to 2044 if granted 19

![](image_059.jpg)

Key Financial Highlights 20 » Cash Position: ~ $3.8 million in cash as of June 30, 2025, funding near term operations and clinical development » Debt - Free Balance Sheet: No outstanding debt, maintaining financial flexibility » Capital Structure: ~2.6 million shares outstanding as of August 2025, following a reverse split to preserve Nasdaq listing compliance » Market Valuation: We believe our m arket capitalization reflects a significant discount to the company's technology, platform and clinical opportunities » Nasdaq Listing Maintained : Shares continue to trade on the Nasdaq Capital Market under ticker AEMD, providing visibility and access to a broad investor base

![](image_060.jpg)

11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD wwwˌAethlonMedicalˌcom 21 This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including: whether and when our products may be successfully developed and introduced; the anticipated market acceptance of the Aethlon Hemopurifier®; and the likelihood of regulatory or manufacturing delays. These risks and uncertainties are detailed in our SEC filings, which are accessible at www.sec.gov or on our website, www.AethlonMedical.com Contact Information